ZYVERSA THERAPEUTICS INC (ZVSA)
US98987D3008 - Common Stock
ZVSA Stock Earnings: ZyVersa Therapeutics Misses EPS for Q1 2024
ZVSA stock results show that ZyVersa Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.
ZVSA Stock Earnings: ZyVersa Therapeutics Misses EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips ZyVersa Therapeutics (NASDAQ:ZVSA) just reported results for the first quarter ...
ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update
ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update
ZyVersa is on track to achieve key development milestones over the next 3 quarters....
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention
To learn more about ZyVersa's Inflammasome ASC Inhibitor and Renal Pipelines, schedule a one-on-one meeting on 2024 BIO International Conference's Portal....
ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s Disease
NLRP1 & pyrin govern inflammation in Alzheimer’s Disease, and release of inflammasome laden extracellular vesicles induces cardiovascular inflammation....
ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes
Inhibiting inflammasome pathways has potential to attenuate atherosclerosis in patients with diabetes, a leading cause of morbidity & mortality....
ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Key Highlights:
ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga’s Virtual Healthcare Summit 2024 on March 20, 2024
Mr. Glover will talk about inflammasomes, and how they trigger development and spread of damaging inflammation, the culprit behind many deadly diseases. ...
ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat Obesity
ZyVersa is developing Inflammasome ASC Inhibitor IC 100, which is designed to inhibit formation of multiple types of inflammasomes, including NLRP3, and...
ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100’s Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications
In obesity, inflammasome activation in fat tissue triggers cell death and release of inflammatory cytokines & ASC Specks, spreading damaging inflammation....
Why Is Intuitive Machines (LUNR) Stock Down 23% Today?
Intuitive Machines stock is falling on Monday as investors in LUNR react to an update on the company's lunar landing last week.
Why Is Aclarion (ACON) Stock Down 19% Today?
Aclarion stock is falling on Monday as investors react to news of a public offering for shares of ACON and a delisting update.
Why Is Freight Technologies (FRGT) Stock Up 25% Today?
Freight Technologies stock is heading higher on Monday with heavy trading of FRGT alongside a collaboration deal with Envases Universales.
Why Is ZyVersa Therapeutics (ZVSA) Stock Up 37% Today?
ZyVersa Therapeutics stock is rising higher on Monday as shares of ZVDA experience heavy pre-market trading this morning.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting the trading week with a breakdown of the biggest pre-market stock movers traders need to know about on Monday morning!
ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option
Activation of multiple inflammasome pathways and extracellular ASC specks contribute to development and progression of common neurological diseases. ...